GlassScriptPhysician profile
Lauren E Kulik
NPI 1205181583
$2,242.70
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,217 · 2020: $673 · 2021: $353.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $319.89 | 2019-2021 | |
| Amgen INC. | $235.62 | 2019-2020 | |
| Novo Nordisk INC | $232.80 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $222.27 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $182.77 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.83 | 2019-2021 | |
| Glaxosmithkline, LLC. | $133.59 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $108.93 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $93.81 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.86 | 2019-2021 | |
| Abbvie INC. | $72.69 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $68.19 | 2019-2021 | |
| Genentech USA, INC. | $42.41 | 2019-2020 | |
| Amarin Pharma, INC. | $41.53 | 2020 | |
| Merck Sharp & Dohme LLC | $40.40 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.50 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $27.83 | 2020-2021 | |
| Allergan, INC. | $27.76 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $27.51 | 2019 | |
| Corcept Therapeutics | $27.49 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $27.25 | 2020 | |
| Lilly USA, LLC | $25.97 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $18.07 | 2021 | |
| Phadia US INC. | $11.73 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Kulik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.